½ÃÀ庸°í¼­
»óǰÄÚµå
1388172

Àΰ£ Ç÷¼ÒÆÇ ¿ëÇØ¹°(hPL) ½ÃÀå Á¡À¯À², ±Ô¸ð, µ¿Çâ, »ê¾÷ ºÐ¼® º¸°í¼­ : À¯Çüº°, ¿ëµµº°, ÃÖÁ¾ ¿ëµµº°, Áö¿ªº°, ºÎ¹®º° ¿¹Ãø(2023-2032³â)

Human Platelet Lysate Market Share, Size, Trends, Industry Analysis Report, By Type (Heparin Based HPL, Heparin Free HPL); By Application; By End-Use; By Region; Segment Forecast, 2023 - 2032

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Polaris Market Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 116 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    



¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

Polaris market researchÀÇ ÃֽŠÁ¶»ç¿¡ µû¸£¸é Àΰ£ Ç÷¼ÒÆÇ ¿ëÇØ¹°(hPL) ¼¼°è ½ÃÀå ±Ô¸ð´Â 2032³â±îÁö 7,474¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ Á¶»ç º¸°í¼­´Â ÇöÀç ½ÃÀå ¿ªÇп¡ ´ëÇÑ ÀÚ¼¼ÇÑ ÀλçÀÌÆ®¿Í ÇâÈÄ ½ÃÀå ¼ºÀå¿¡ ´ëÇÑ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

Àΰ£ Ç÷¼ÒÆÇ ¿ëÇØ¹°(hPL)Àº ¼¼Æ÷¹è¾ç ¹× Àç»ýÀÇ·á ºÐ¾ß¿¡ »ç¿ëµÇ´Â »ý¹°ÇÐÀû À¯·¡ Á¦Ç°ÀÔ´Ï´Ù. Ç÷¾× ÀÀ°í¿Í »óó Ä¡À¯¿¡ °ü¿©ÇÏ´Â Ç÷¾× ¼¼Æ÷ÀÇ ÀÏÁ¾ÀÎ Àΰ£ Ç÷¼ÒÆÇÀ» °¡°øÇÏ¿© ¸¸µé¾îÁö¸ç, hPLÀº ´Ù¾çÇÑ ¼ºÀåÀÎÀÚ¿Í »ý¸®È°¼º ºÐÀÚ¸¦ ÇÔÀ¯Çϰí ÀÖ¾î ¼¼Æ÷ÀÇ ¼ºÀåÀ» ÃËÁøÇÏ°í ´Ù¾çÇÑ Á¾·ùÀÇ ¼¼Æ÷¿¡ ¿µ¾çÀÌ Ç³ºÎÇÑ È¯°æÀ» Á¦°øÇÕ´Ï´Ù.

ÆÄŲ½¼º´, °ñ°üÀý¿°, ³²¼ºÇü Å»¸ðÁõ°ú °°Àº ¸¸¼º ÁúȯÀÇ Áõ°¡´Â Ç÷¼ÒÆÇ ¿ëÇØ¹° ½ÃÀå¿¡ Å« ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¸¸¼º ÁúȯÀº Çõ½ÅÀûÀ̰í È¿°úÀûÀÎ Ä¡·á ¿É¼Ç¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡·Î À̾îÁ® Àç»ý ÀÇÇÐÀÇ ¿¬±¸ °³¹ßÀ» ÃËÁøÇÏ¿© Ç÷¼ÒÆÇ ¿ëÇØ¹° ½ÃÀå¿¡ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù.

È¿À²¼º ¶ÇÇÑ hPLÀÇ Ã¤ÅÃÀ» ÃËÁøÇÏ´Â ¼³µæ·Â ÀÖ´Â ¿äÀÎÀ¸·Î, ¿¬±¸¿¡ µû¸£¸é hPLÀº ¼¼Æ÷ ¼ºÀå, »ýÁ¸À² ¹× ±â´É Áö¿ø Ãø¸é¿¡¼­ FBS¸¦ ´É°¡ÇÏ´Â °ÍÀ¸·Î ³ªÅ¸³µ½À´Ï´Ù. ¿¬±¸ÀÚµéÀº hPLÀ» »ç¿ëÇÏ¸é ´õ °ß°íÇÏ°í ½Å·ÚÇÒ ¼ö ÀÖ´Â ½ÇÇè °á°ú¸¦ ¾òÀ» ¼ö Àֱ⠶§¹®¿¡ ¼¼Æ÷ Áõ½Ä·üÀÌ Çâ»óµÇ°í ¼¼Æ÷ ±â´ÉÀÌ °³¼±µÇ´Â °ÍÀ» °üÂûÇß½À´Ï´Ù. ÀÌ·¯ÇÑ È¿À²¼º Çâ»óÀº ¹è¾çµÈ ¼¼Æ÷ÀÇ Ç°ÁúÀÌ Ä¡·á ¹× Ä¡·áÀÇ ¼º°ø¿¡ Á÷Á¢ÀûÀÎ ¿µÇâÀ» ¹ÌÄ¡´Â Àç»ýÀÇ·á¿Í °°Àº ºÐ¾ß¿¡¼­ ƯÈ÷ °¡Ä¡°¡ ÀÖ½À´Ï´Ù.

À¯Àü¼º Å»¸ðÁõÀÎ ³²¼ºÇü Å»¸ðÁõµµ Ç÷¼ÒÆÇ ¿ëÇØ¹° ±â¹Ý ¼Ö·ç¼Ç¿¡ ´ëÇÑ °ü½ÉÀ» ³ôÀ̰í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, ¹Ì±¹¿¡¼­´Â ¾à 5,000¸¸ ¸íÀÇ ³²¼º°ú 3,000¸¸ ¸íÀÇ ¿©¼ºÀÌ ³²¼ºÇü Å»¸ðÁõÀÇ ¿µÇâÀ» ¹Þ´Â °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù. ÀÌ Áõ»óÀº ºü¸£¸é 10´ëºÎÅÍ ½ÃÀÛµÇ°í ³ªÀ̰¡ µé¼ö·Ï ¹ß»ýÇϱ⠽¬¿öÁö¸ç, 50¼¼ ÀÌ»óÀÌ¸é ³²¼ºÀÇ 50% ÀÌ»óÀÌ ¾î´À Á¤µµ Å»¸ð¸¦ °æÇèÇÕ´Ï´Ù. ¹Ì±¹ º¸°Çº¹ÁöºÎ¿¡ µû¸£¸é ¿©¼ºÀÇ °æ¿ì Æó°æ±â ÀÌÈÄ Å»¸ð°¡ ´õ ¸¹ÀÌ ¹ß»ýÇÏ´Â °æÇâÀÌ ÀÖ½À´Ï´Ù. Ç÷¼ÒÆÇ ¿ëÇØ¹°¿¡¼­ ÃßÃâÇÑ Ç÷¼ÒÆÇdzºÎÇ÷Àå(PRP)Àº ¸ð³¶ÀÇ Àç»ýÀ» ÃËÁøÇÏ°í ¹ß¸ð¸¦ ÃËÁøÇÒ °ÍÀ¸·Î ±â´ëµÇ°í ÀÖ½À´Ï´Ù. Å»¸ð¿¡ ´ëÇÑ È¿°úÀûÀÌ°í ºñħ½ÀÀûÀÎ Ä¡·á¹ýÀ» ã´Â »ç¶÷µéÀÌ ´Ã¾î³ª¸é¼­ Ç÷¼ÒÆÇ ¿ëÇØ¹° ±â¹Ý ¸ð¹ß Àç»ý¼ú ½ÃÀåÀÌ Å©°Ô È®´ëµÇ°í ÀÖ½À´Ï´Ù.

ÀÌ·¯ÇÑ Æ¯Á¤ Áõ»ó»Ó¸¸ ¾Æ´Ï¶ó ¸¸¼º Áúȯ°ú ³ëÈ­¿Í °ü·ÃµÈ ´Ù¾çÇÑ °Ç°­ ¹®Á¦°¡ Áõ°¡ÇÔ¿¡ µû¶ó ±Ùº»ÀûÀÎ ¿øÀÎÀ» ÇØ°áÇϰí Àå±âÀûÀÎ Ä¡·á¹ýÀ» Á¦°øÇÒ ¼ö ÀÖ´Â Àç»ýÀÇ·á¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¾Æ·¡ ±×·¡ÇÁ´Â »õ·Î¿î Àç»ý ÀÇÇÐ ¹× Ä¡·á¹ý °³¹ßÀ» ÃËÁøÇÏ´Â ¸¸¼º ÁúȯÀÇ Áõ°¡¸¦ ¿¹ÃøÇÑ °ÍÀÔ´Ï´Ù. Àç»ý Ư¼ºÀ» °¡Áø Ç÷¼ÒÆÇ ¿ëÇØ¹°Àº ¼Õ»óµÈ Á¶Á÷À» º¹±¸Çϰí, ¸é¿ª ¹ÝÀÀÀ» Á¶ÀýÇϸç, Àü¹ÝÀûÀΠȯÀÚ °á°ú¸¦ °³¼±ÇÏ´Â °ÍÀ» ¸ñÇ¥·Î ÇÏ´Â ¼¼Æ÷ ±â¹Ý Ä¡·á¹ýÀ» °³¹ßÇÏ´Â µ¥ ÀÖ¾î ±ÍÁßÇÑ µµ±¸°¡ µÇ°í ÀÖ½À´Ï´Ù.

Àΰ£ Ç÷¼ÒÆÇ ¿ëÇØ¹°(hPL) ½ÃÀå º¸°í¼­ ÇÏÀ̶óÀÌÆ®

ÇìÆÄ¸° ÇÁ¸® hPL ºÎ¹®Àº 2022³â ÇìÆÄ¸° ÇÔÀ¯ Á¦Ç°À» ´ëüÇÒ ¼ö ÀÖ´Â ¾ÈÀü¼º, ½Å·Ú¼º, À¯È¿¼ºÀ¸·Î ÀÎÇØ °¡Àå Å« ¸ÅÃâ Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.

Ä¡·á ºÐ¾ß´Â Àç»ýÀÇÇÐ, »óó Ä¡À¯, ¾È°ú, ½Å°æÁúȯ, ¾Ï Ä¡·á µî ´Ù¾çÇϰí À¯¸ÁÇÑ ÀÀ¿ë ºÐ¾ß·Î ÀÎÇØ ¿¹Ãø ±â°£ µ¿¾È °¡Àå ºü¸¥ ½ÃÀå ¼ºÀåÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ´Ù¾çÇÑ Ä¡·á Á¢±Ù¹ýÀ» °­È­ÇÒ ¼ö ÀÖ´Â ´Ù¸ñÀû¼º°ú °¡´É¼ºÀ¸·Î ÀÎÇØ ƯÁ¤ ÀÓ»ó »óȲ¿¡¼­´Â ½ÅÁßÇÑ °ËÅä°¡ ÇÊ¿äÇÏÁö¸¸ ÀÇÇÐ ¿¬±¸ ¹× ÀÓ»ó ºÐ¾ß¿¡¼­ ±ÍÁßÇÑ µµ±¸°¡ µÇ°í ÀÖ½À´Ï´Ù.

2022³â ºÏ¹Ì°¡ °¡Àå Å« ½ÃÀåÀ» Â÷ÁöÇߴµ¥, ÀÌ´Â »ý¹° ÀÇÇÐ ¿¬±¸, Àç»ý ÀÇÇÐ ¹× ¼¼Æ÷ Ä¡·á ±â¼úÀÇ ¹ßÀü¿¡ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí Àֱ⠶§¹®ÀÔ´Ï´Ù. ±ÔÁ¦ ´ç±¹ÀÇ °¨µ¶À» ÅëÇØ ÀÌ·¯ÇÑ Çõ½ÅÀûÀÎ Ä¡·á¹ýÀÌ À±¸®ÀûÀÌ°í ¾ÈÀüÇÏ°Ô °³¹ßµÉ ¼ö ÀÖµµ·Ï º¸ÀåÇϱ⠶§¹®¿¡ ºÏ¹Ì´Â hPL ¼¼°è ½ÃÀå¿¡¼­ ÁÖ¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­·Ð

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå Á¶»ç ¹æ¹ý

Á¦4Àå ¼¼°èÀÇ Àΰ£ Ç÷¼ÒÆÇ ¿ëÇØ¹°(hPL) ½ÃÀå¿¡ °üÇÑ ÀλçÀÌÆ®

  • Àΰ£ Ç÷¼ÒÆÇ ¿ëÇØ¹°(hPL) ½ÃÀå - ÃÖÁ¾ ¿ëµµ ÇöȲ
  • Àΰ£ Ç÷¼ÒÆÇ ¿ëÇØ¹°(hPL) ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀΰú ±âȸ
      • ÁÖ¿ä ±â¾÷À̳ª Á¤ºÎ¿¡ ÀÇÇÑ Áٱ⼼Æ÷ Ä¡·á ¿¬±¸°³¹ß(R&D) Ȱµ¿ÀÌ Áõ°¡
      • ÆÄŲ½¼º´, °ñ°üÀý¿°, ³²¼ºÇü Å»¸ð µîÀÇ ¸¸¼ºÁúȯ À¯º´·ü Áõ°¡
    • ¼ºÀå ¾ïÁ¦¿äÀΰú °úÁ¦
      • ºñ¿ëÀÌ ³ô°í, Àü¿°º´ ÀüÆÄ ¸®½ºÅ©°¡ Áõ°¡
  • PESTEL ºÐ¼®
  • Àΰ£ Ç÷¼ÒÆÇ ¿ëÇØ¹°(hPL) ½ÃÀå ÃÖÁ¾ ¿ëµµ µ¿Çâ
  • ¹ë·ùüÀÎ ºÐ¼®
  • COVID-19ÀÇ ¿µÇ⠺м®

Á¦5Àå ¼¼°èÀÇ Àΰ£ Ç÷¼ÒÆÇ ¿ëÇØ¹°(hPL) ½ÃÀå, À¯Çüº°

  • ÁÖ¿ä Á¶»ç °á°ú
  • ¼­·Ð
  • ÇìÆÄ¸° ±â¹Ý hPL
  • ÇìÆÄ¸° ÇÁ¸® hPL

Á¦6Àå ¼¼°èÀÇ Àΰ£ Ç÷¼ÒÆÇ ¿ëÇØ¹°(hPL) ½ÃÀå, ¿ëµµº°

  • ÁÖ¿ä Á¶»ç °á°ú
  • ¼­·Ð
  • ¿¬±¸
  • Ä¡·á

Á¦7Àå ¼¼°èÀÇ Àΰ£ Ç÷¼ÒÆÇ ¿ëÇØ¹°(hPL) ½ÃÀå, ÃÖÁ¾ ¿ëµµº°

  • ÁÖ¿ä Á¶»ç °á°ú
  • ¼­·Ð
  • Á¦¾à¡¤¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷
  • Çмú¡¤¿¬±¸±â°ü
  • ±âŸ

Á¦8Àå ¼¼°èÀÇ Àΰ£ Ç÷¼ÒÆÇ ¿ëÇØ¹°(hPL) ½ÃÀå, Áö¿ªº°

  • ÁÖ¿ä Á¶»ç °á°ú
  • ¼­·Ð
    • Àΰ£ Ç÷¼ÒÆÇ ¿ëÇØ¹°(hPL) ½ÃÀå Æò°¡, Áö¿ªº°, 2019-2032³â
  • Àΰ£ Ç÷¼ÒÆÇ ¿ëÇØ¹°(hPL) ½ÃÀå - ºÏ¹Ì
    • ºÏ¹Ì : Àΰ£ Ç÷¼ÒÆÇ ¿ëÇØ¹°(hPL) ½ÃÀå, À¯Çüº°, 2019-2032³â
    • ºÏ¹Ì : Àΰ£ Ç÷¼ÒÆÇ ¿ëÇØ¹°(hPL) ½ÃÀå, ÃÖÁ¾ ¿ëµµº°, 2019-2032³â
    • ºÏ¹Ì : Àΰ£ Ç÷¼ÒÆÇ ¿ëÇØ¹°(hPL) ½ÃÀå, ¿ëµµº°, 2019-2032³â
    • Àΰ£ Ç÷¼ÒÆÇ ¿ëÇØ¹°(hPL) ½ÃÀå - ¹Ì±¹
    • Àΰ£ Ç÷¼ÒÆÇ ¿ëÇØ¹°(hPL) ½ÃÀå - ij³ª´Ù
  • Àΰ£ Ç÷¼ÒÆÇ ¿ëÇØ¹°(hPL) ½ÃÀå - À¯·´
    • À¯·´ : Àΰ£ Ç÷¼ÒÆÇ ¿ëÇØ¹°(hPL) ½ÃÀå, À¯Çüº°, 2019-2032³â
    • À¯·´ : Àΰ£ Ç÷¼ÒÆÇ ¿ëÇØ¹°(hPL) ½ÃÀå, ÃÖÁ¾ ¿ëµµº°, 2019-2032³â
    • À¯·´ : Àΰ£ Ç÷¼ÒÆÇ ¿ëÇØ¹°(hPL) ½ÃÀå, ¿ëµµº°, 2019-2032³â
    • Àΰ£ Ç÷¼ÒÆÇ ¿ëÇØ¹°(hPL) ½ÃÀå - ¿µ±¹
    • Àΰ£ Ç÷¼ÒÆÇ ¿ëÇØ¹°(hPL) ½ÃÀå - ÇÁ¶û½º
    • Àΰ£ Ç÷¼ÒÆÇ ¿ëÇØ¹°(hPL) ½ÃÀå - µ¶ÀÏ
    • Àΰ£ Ç÷¼ÒÆÇ ¿ëÇØ¹°(hPL) ½ÃÀå - ÀÌÅ»¸®¾Æ
    • Àΰ£ Ç÷¼ÒÆÇ ¿ëÇØ¹°(hPL) ½ÃÀå - ½ºÆäÀÎ
    • Àΰ£ Ç÷¼ÒÆÇ ¿ëÇØ¹°(hPL) ½ÃÀå - ³×µ¨¶õµå
    • Àΰ£ Ç÷¼ÒÆÇ ¿ëÇØ¹°(hPL) ½ÃÀå - ·¯½Ã¾Æ
  • Àΰ£ Ç÷¼ÒÆÇ ¿ëÇØ¹°(hPL) ½ÃÀå - ¾Æ½Ã¾ÆÅÂÆò¾ç
    • ¾Æ½Ã¾ÆÅÂÆò¾ç : Àΰ£ Ç÷¼ÒÆÇ ¿ëÇØ¹°(hPL) ½ÃÀå, À¯Çüº°, 2019-2032³â
    • ¾Æ½Ã¾ÆÅÂÆò¾ç : Àΰ£ Ç÷¼ÒÆÇ ¿ëÇØ¹°(hPL) ½ÃÀå, ÃÖÁ¾ ¿ëµµº°, 2019-2032³â
    • ¾Æ½Ã¾ÆÅÂÆò¾ç : Àΰ£ Ç÷¼ÒÆÇ ¿ëÇØ¹°(hPL) ½ÃÀå, ¿ëµµº°, 2019-2032³â
    • Àΰ£ Ç÷¼ÒÆÇ ¿ëÇØ¹°(hPL) ½ÃÀå - Áß±¹
    • Àΰ£ Ç÷¼ÒÆÇ ¿ëÇØ¹°(hPL) ½ÃÀå - Àεµ
    • Àΰ£ Ç÷¼ÒÆÇ ¿ëÇØ¹°(hPL) ½ÃÀå - ¸»·¹À̽þÆ
    • Àΰ£ Ç÷¼ÒÆÇ ¿ëÇØ¹°(hPL) ½ÃÀå - ÀϺ»
    • Àΰ£ Ç÷¼ÒÆÇ ¿ëÇØ¹°(hPL) ½ÃÀå - Àεµ³×½Ã¾Æ
    • Àΰ£ Ç÷¼ÒÆÇ ¿ëÇØ¹°(hPL) ½ÃÀå - Çѱ¹
  • Àΰ£ Ç÷¼ÒÆÇ ¿ëÇØ¹°(hPL) ½ÃÀå - Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : Àΰ£ Ç÷¼ÒÆÇ ¿ëÇØ¹°(hPL) ½ÃÀå, À¯Çüº°, 2019-2032³â
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : Àΰ£ Ç÷¼ÒÆÇ ¿ëÇØ¹°(hPL) ½ÃÀå, ÃÖÁ¾ ¿ëµµº°, 2019-2032³â
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : Àΰ£ Ç÷¼ÒÆÇ ¿ëÇØ¹°(hPL) ½ÃÀå, ¿ëµµº°, 2019-2032³â
    • Àΰ£ Ç÷¼ÒÆÇ ¿ëÇØ¹°(hPL) ½ÃÀå - »ç¿ìµð¾Æ¶óºñ¾Æ
    • Àΰ£ Ç÷¼ÒÆÇ ¿ëÇØ¹°(hPL) ½ÃÀå - ¾Æ¶ø¿¡¹Ì¸®Æ®
    • Àΰ£ Ç÷¼ÒÆÇ ¿ëÇØ¹°(hPL) ½ÃÀå - À̽º¶ó¿¤
    • Àΰ£ Ç÷¼ÒÆÇ ¿ëÇØ¹°(hPL) ½ÃÀå - ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
  • Àΰ£ Ç÷¼ÒÆÇ ¿ëÇØ¹°(hPL) ½ÃÀå - ¶óƾ¾Æ¸Þ¸®Ä«
    • ¶óƾ¾Æ¸Þ¸®Ä« : Àΰ£ Ç÷¼ÒÆÇ ¿ëÇØ¹°(hPL) ½ÃÀå, À¯Çüº°, 2019-2032³â
    • ¶óƾ¾Æ¸Þ¸®Ä« : Àΰ£ Ç÷¼ÒÆÇ ¿ëÇØ¹°(hPL) ½ÃÀå, ÃÖÁ¾ ¿ëµµº°, 2019-2032³â
    • ¶óƾ¾Æ¸Þ¸®Ä« : Àΰ£ Ç÷¼ÒÆÇ ¿ëÇØ¹°(hPL) ½ÃÀå, ¿ëµµº°, 2019-2032³â
    • Àΰ£ Ç÷¼ÒÆÇ ¿ëÇØ¹°(hPL) ½ÃÀå - ¸ß½ÃÄÚ
    • Àΰ£ Ç÷¼ÒÆÇ ¿ëÇØ¹°(hPL) ½ÃÀå - ºê¶óÁú
    • Àΰ£ Ç÷¼ÒÆÇ ¿ëÇØ¹°(hPL) ½ÃÀå - ¾Æ¸£ÇîÆ¼³ª

Á¦9Àå °æÀï »óȲ

  • È®Àå°ú Àμö ºÐ¼®
    • È®´ë
    • Àμö
  • Á¦ÈÞ/Çù¾÷/ÇÕÀÇ/°ø°³

Á¦10Àå ±â¾÷ °³¿ä

  • AventaCell BioMedical Corp
  • Compass Biomedical Inc.
  • Lifescience Group Limited
  • Macopharma SA
  • Merck KGaA
  • Mill Creek Lifesciences LLC
  • Sclavo Diagnostics International Srl
  • Stem Cell Technologies Inc
  • Trinova Biochem GmbH
  • Zen Bio, Inc.
ksm 23.12.13

The global human platelet lysate market size is expected to reach USD 74.74 million by 2032, according to a new study by Polaris market research. The report "Human Platelet Lysate Market Share, Size, Trends, Industry Analysis Report, By Type (Heparin Based HPL, Heparin Free HPL); By Application; By End-Use; By Region; Segment Forecast, 2023 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Human Platelet Lysate (HPL) is a biologically derived product used in cell culture and regenerative medicine applications. It is created by processing human platelets, a type of blood cell involved in clotting and wound healing. HPL contains various growth factors and bioactive molecules that promote cell growth and provide a nutrient-rich environment for various cell types.

The increasing prevalence of chronic diseases, including but not limited to Parkinson's disease, osteoarthritis, and androgenetic alopecia, has significantly impacted the platelet lysate market. These chronic conditions have led to a growing demand for innovative and effective treatment options, driving research and development efforts in regenerative medicine and thereby, influencing the market for platelet lysate.

Efficiency is another compelling factor fueling the adoption of HPL. Studies have shown that HPL can often outperform FBS in terms of supporting cell growth, viability, and functionality. Researchers have observed enhanced cell expansion rates and improved cellular functions when using HPL, due to more robust and reliable experimental results. This heightened efficiency is particularly valuable in fields like regenerative medicine, where the quality of cultured cells directly impacts the success of therapies and treatments.

Androgenetic alopecia, a hereditary form of hair loss, has also driven interest in platelet lysate-based solutions. For instance, approximately 50 million men and 30 million women in the United States are believed to be impacted by androgenetic alopecia. This condition can commence as early as a person's teenage years and becomes more likely as they age. Beyond the age of 50, over 50 percent of men experience some level of hair loss. In the case of women, hair loss tends to be more common following menopause, according to U.S. Department of Health and Human Services. Platelet-rich plasma (PRP), derived from platelet lysate, has shown promise in stimulating hair follicle regeneration and promoting hair growth. As individuals seek effective and non-invasive treatments for hair loss, the market for platelet lysate-based hair restoration procedures has grown substantially.

Beyond these specific conditions, the broader rise in chronic diseases and age-related health issues has created a demand for regenerative therapies that can address the root causes and provide long-term relief. The below graph predicts the rising number of chronic diseases that urge for developing new regenerative medicines and therapies. Since Platelet lysate, with its regenerative properties, has become a valuable tool in the development of cell-based treatments that aim to repair damaged tissues, modulate immune responses, and improve overall patient outcomes.

Human Platelet Lysate Market Report Highlights

In 2022, the heparin free HPL segment held the largest revenue share due to its safety, reliability, and effectiveness as an alternative to heparin-containing products.

The therapeutic segment expected to witness the fastest market during the forecast period due to its diverse and promising applications in regenerative medicine, wound healing, ophthalmology, neurological disorders, and even cancer therapy. Its versatility and potential to enhance various therapeutic approaches make it a valuable tool in the field of medical research and clinical practice, albeit with careful consideration in certain clinical contexts.

In 2022, North America dominated the largest market due to region's focus on biomedical research, regenerative medicine, and its significant role in advancing cell therapy techniques. Regulatory oversight ensures the ethical and safe development of these innovative therapies, making North America a key player in the global market for HPL.

The global key market players include: Merck KGaA, Compass Biomedical Inc., AventaCell BioMedical Corp, Mill Creek Lifesciences LLC, Stem Cell Technologies Inc., Zen Bio, Inc., Sclavo Diagnostics International Srl, Lifescience Group Limited, and Trinova Biochem GmbH.

Polaris market research has segmented the human platelet lysate market report based on type, application, end-use, and region:

Human Platelet Lysate, Type Outlook (Revenue - USD Million, 2019 - 2032)

  • Heparin Based HPL
  • Heparin Free HPL

Human Platelet Lysate, Application Outlook (Revenue - USD Million, 2019 - 2032)

  • Research
  • Therapeutic

Human Platelet Lysate, End-Use Outlook (Revenue - USD Million, 2019 - 2032)

  • Pharmaceutical & Biotechnological Companies
  • Academic & Research Institutes
  • Others

Human Platelet Lysate, Regional Outlook (Revenue - USD Million, 2019 - 2032)

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Human Platelet Lysate Market Insights

  • 4.1. Human Platelet Lysate Market - End-Use Snapshot
  • 4.2. Human Platelet Lysate Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Increasing In the Research and Development (R&D) Activities of Stem Cell Therapy by Major Companies and Governments
      • 4.2.1.2. Increasing prevalence of chronic diseases such as Parkinson's disease, osteoarthritis, androgenetic alopecia and others
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. High cost and increased risk of transmission of infectious communicable diseases
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Human Platelet Lysate Market End-Use Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Human Platelet Lysate Market, by Type

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Human Platelet Lysate Market, by Type, 2019-2032 (USD Million)
  • 5.3. Heparin Based HPL
    • 5.3.1. Global Human Platelet Lysate Market, by Heparin Based HPL, by Region, 2019-2032 (USD Million)
  • 5.4. Heparin Free HPL
    • 5.4.1. Global Human Platelet Lysate Market, by Heparin Free HPL, by Region, 2019-2032 (USD Million)

6. Global Human Platelet Lysate Market, by Application

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Human Platelet Lysate Market, by Application, 2019-2032 (USD Million)
  • 6.3. Research
    • 6.3.1. Global Human Platelet Lysate Market, by Research, by Region, 2019-2032 (USD Million)
  • 6.4. Therapeutic
    • 6.4.1. Global Human Platelet Lysate Market, by Therapeutic, by Region, 2019-2032 (USD Million)

7. Global Human Platelet Lysate Market, by End-Use

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Human Platelet Lysate Market, by End-Use, 2019-2032 (USD Million)
  • 7.3. Pharmaceutical & Biotechnological Companies
    • 7.3.1. Global Human Platelet Lysate Market, by Pharmaceutical & Biotechnological Companies, By Region, 2019-2032 (USD Million)
  • 7.4. Academic & Research Institutes
    • 7.4.1. Global Human Platelet Lysate Market, by Academic & Research Institutes, By Region, 2019-2032 (USD Million)
  • 7.5. Others
    • 7.5.1. Global Human Platelet Lysate Market, by Others, By Region, 2019-2032 (USD Million)

8. Global Human Platelet Lysate Market, by Geography

  • 8.1. Key findings
  • 8.2. Introduction
    • 8.2.1. Human Platelet Lysate Market Assessment, By Geography, 2019-2032 (USD Million)
  • 8.3. Human Platelet Lysate Market - North America
    • 8.3.1. North America: Human Platelet Lysate Market, by Type, 2019-2032 (USD Million)
    • 8.3.2. North America: Human Platelet Lysate Market, by End-Use, 2019-2032 (USD Million)
    • 8.3.3. North America: Human Platelet Lysate Market, by Application, 2019-2032 (USD Million)
    • 8.3.4. Human Platelet Lysate Market - U.S.
      • 8.3.4.1. U.S.: Human Platelet Lysate Market, by Type, 2019-2032 (USD Million)
      • 8.3.4.2. U.S.: Human Platelet Lysate Market, by End-Use, 2019-2032 (USD Million)
      • 8.3.4.3. U.S.: Human Platelet Lysate Market, by Application, 2019-2032 (USD Million)
    • 8.3.5. Human Platelet Lysate Market - Canada
      • 8.3.5.1. Canada: Human Platelet Lysate Market, by Type, 2019-2032 (USD Million)
      • 8.3.5.2. Canada.: Human Platelet Lysate Market, by End-Use, 2019-2032 (USD Million)
      • 8.3.5.3. Canada: Human Platelet Lysate Market, by Application, 2019-2032 (USD Million)
  • 8.4. Human Platelet Lysate Market - Europe
    • 8.4.1. Europe: Human Platelet Lysate Market, by Type, 2019-2032 (USD Million)
    • 8.4.2. Europe.: Human Platelet Lysate Market, by End-Use, 2019-2032 (USD Million)
    • 8.4.3. Europe: Human Platelet Lysate Market, by Application, 2019-2032 (USD Million)
    • 8.4.4. Human Platelet Lysate Market - UK
      • 8.4.4.1. UK: Human Platelet Lysate Market, by Type, 2019-2032 (USD Million)
      • 8.4.4.2. UK.: Human Platelet Lysate Market, by End-Use, 2019-2032 (USD Million)
      • 8.4.4.3. UK: Human Platelet Lysate Market, by Application, 2019-2032 (USD Million)
    • 8.4.5. Human Platelet Lysate Market - France
      • 8.4.5.1. France: Human Platelet Lysate Market, by Type, 2019-2032 (USD Million)
      • 8.4.5.2. France.: Human Platelet Lysate Market, by End-Use, 2019-2032 (USD Million)
      • 8.4.5.3. France: Human Platelet Lysate Market, by Application, 2019-2032 (USD Million)
    • 8.4.6. Human Platelet Lysate Market - Germany
      • 8.4.6.1. Germany: Human Platelet Lysate Market, by Type, 2019-2032 (USD Million)
      • 8.4.6.2. Germany.: Human Platelet Lysate Market, by End-Use, 2019-2032 (USD Million)
      • 8.4.6.3. Germany: Human Platelet Lysate Market, by Application, 2019-2032 (USD Million)
    • 8.4.7. Human Platelet Lysate Market - Italy
      • 8.4.7.1. Italy: Human Platelet Lysate Market, by Type, 2019-2032 (USD Million)
      • 8.4.7.2. Italy.: Human Platelet Lysate Market, by End-Use, 2019-2032 (USD Million)
      • 8.4.7.3. Italy: Human Platelet Lysate Market, by Application, 2019-2032 (USD Million)
    • 8.4.8. Human Platelet Lysate Market - Spain
      • 8.4.8.1. Spain: Human Platelet Lysate Market, by Type, 2019-2032 (USD Million)
      • 8.4.8.2. Spain.: Human Platelet Lysate Market, by End-Use, 2019-2032 (USD Million)
      • 8.4.8.3. Spain: Human Platelet Lysate Market, by Application, 2019-2032 (USD Million)
    • 8.4.9. Human Platelet Lysate Market - Netherlands
      • 8.4.9.1. Netherlands: Human Platelet Lysate Market, by Type, 2019-2032 (USD Million)
      • 8.4.9.2. Netherlands.: Human Platelet Lysate Market, by End-Use, 2019-2032 (USD Million)
      • 8.4.9.3. Netherlands: Human Platelet Lysate Market, by Application, 2019-2032 (USD Million)
    • 8.4.10. Human Platelet Lysate Market - Russia
      • 8.4.10.1. Russia: Human Platelet Lysate Market, by Type, 2019-2032 (USD Million)
      • 8.4.10.2. Russia.: Human Platelet Lysate Market, by End-Use, 2019-2032 (USD Million)
      • 8.4.10.3. Russia: Human Platelet Lysate Market, by Application, 2019-2032 (USD Million)
  • 8.5. Human Platelet Lysate Market - Asia Pacific
    • 8.5.1. Asia Pacific: Human Platelet Lysate Market, by Type, 2019-2032 (USD Million)
    • 8.5.2. Asia Pacific.: Human Platelet Lysate Market, by End-Use, 2019-2032 (USD Million)
    • 8.5.3. Asia Pacific: Human Platelet Lysate Market, by Application, 2019-2032 (USD Million)
    • 8.5.4. Human Platelet Lysate Market - China
      • 8.5.4.1. China: Human Platelet Lysate Market, by Type, 2019-2032 (USD Million)
      • 8.5.4.2. China.: Human Platelet Lysate Market, by End-Use, 2019-2032 (USD Million)
      • 8.5.4.3. China: Human Platelet Lysate Market, by Application, 2019-2032 (USD Million)
    • 8.5.5. Human Platelet Lysate Market - India
      • 8.5.5.1. India: Human Platelet Lysate Market, by Type, 2019-2032 (USD Million)
      • 8.5.5.2. India.: Human Platelet Lysate Market, by End-Use, 2019-2032 (USD Million)
      • 8.5.5.3. India: Human Platelet Lysate Market, by Application, 2019-2032 (USD Million)
    • 8.5.6. Human Platelet Lysate Market - Malaysia
      • 8.5.6.1. Malaysia: Human Platelet Lysate Market, by Type, 2019-2032 (USD Million)
      • 8.5.6.2. Malaysia.: Human Platelet Lysate Market, by End-Use, 2019-2032 (USD Million)
      • 8.5.6.3. Malaysia: Human Platelet Lysate Market, by Application, 2019-2032 (USD Million)
    • 8.5.7. Human Platelet Lysate Market - Japan
      • 8.5.7.1. Japan: Human Platelet Lysate Market, by Type, 2019-2032 (USD Million)
      • 8.5.7.2. Japan.: Human Platelet Lysate Market, by End-Use, 2019-2032 (USD Million)
      • 8.5.7.3. Japan: Human Platelet Lysate Market, by Application, 2019-2032 (USD Million)
    • 8.5.8. Human Platelet Lysate Market - Indonesia
      • 8.5.8.1. Indonesia: Human Platelet Lysate Market, by Type, 2019-2032 (USD Million)
      • 8.5.8.2. Indonesia.: Human Platelet Lysate Market, by End-Use, 2019-2032 (USD Million)
      • 8.5.8.3. Indonesia: Human Platelet Lysate Market, by Application, 2019-2032 (USD Million)
    • 8.5.9. Human Platelet Lysate Market - South Korea
      • 8.5.9.1. South Korea: Human Platelet Lysate Market, by Type, 2019-2032 (USD Million)
      • 8.5.9.2. South Korea.: Human Platelet Lysate Market, by End-Use, 2019-2032 (USD Million)
      • 8.5.9.3. South Korea: Human Platelet Lysate Market, by Application, 2019-2032 (USD Million)
  • 8.6. Human Platelet Lysate Market - Middle East & Africa
    • 8.6.1. Middle East & Africa: Human Platelet Lysate Market, by Type, 2019-2032 (USD Million)
    • 8.6.2. Middle East & Africa.: Human Platelet Lysate Market, by End-Use, 2019-2032 (USD Million)
    • 8.6.3. Middle East & Africa: Human Platelet Lysate Market, by Application, 2019-2032 (USD Million)
    • 8.6.4. Human Platelet Lysate Market - Saudi Arabia
      • 8.6.4.1. Saudi Arabia: Human Platelet Lysate Market, by Type, 2019-2032 (USD Million)
      • 8.6.4.2. Saudi Arabia.: Human Platelet Lysate Market, by End-Use, 2019-2032 (USD Million)
      • 8.6.4.3. Saudi Arabia: Human Platelet Lysate Market, by Application, 2019-2032 (USD Million)
    • 8.6.5. Human Platelet Lysate Market - UAE
      • 8.6.5.1. UAE: Human Platelet Lysate Market, by Type, 2019-2032 (USD Million)
      • 8.6.5.2. UAE.: Human Platelet Lysate Market, by End-Use, 2019-2032 (USD Million)
      • 8.6.5.3. UAE: Human Platelet Lysate Market, by Application, 2019-2032 (USD Million)
    • 8.6.6. Human Platelet Lysate Market - Israel
      • 8.6.6.1. Israel: Human Platelet Lysate Market, by Type, 2019-2032 (USD Million)
      • 8.6.6.2. Israel.: Human Platelet Lysate Market, by End-Use, 2019-2032 (USD Million)
      • 8.6.6.3. Israel: Human Platelet Lysate Market, by Application, 2019-2032 (USD Million)
    • 8.6.7. Human Platelet Lysate Market - South Africa
      • 8.6.7.1. South Africa: Human Platelet Lysate Market, by Type, 2019-2032 (USD Million)
      • 8.6.7.2. South Africa.: Human Platelet Lysate Market, by End-Use, 2019-2032 (USD Million)
      • 8.6.7.3. South Africa: Human Platelet Lysate Market, by Application, 2019-2032 (USD Million)
  • 8.7. Human Platelet Lysate Market - Latin America
    • 8.7.1. Latin America: Human Platelet Lysate Market, by Type, 2019-2032 (USD Million)
    • 8.7.2. Latin America.: Human Platelet Lysate Market, by End-Use, 2019-2032 (USD Million)
    • 8.7.3. Latin America: Human Platelet Lysate Market, by Application, 2019-2032 (USD Million)
    • 8.7.4. Human Platelet Lysate Market - Mexico
      • 8.7.4.1. Mexico: Human Platelet Lysate Market, by Type, 2019-2032 (USD Million)
      • 8.7.4.2. Mexico.: Human Platelet Lysate Market, by End-Use, 2019-2032 (USD Million)
      • 8.7.4.3. Mexico: Human Platelet Lysate Market, by Application, 2019-2032 (USD Million)
    • 8.7.5. Human Platelet Lysate Market - Brazil
      • 8.7.5.1. Brazil: Human Platelet Lysate Market, by Type, 2019-2032 (USD Million)
      • 8.7.5.2. Brazil.: Human Platelet Lysate Market, by End-Use, 2019-2032 (USD Million)
      • 8.7.5.3. Brazil: Human Platelet Lysate Market, by Application, 2019-2032 (USD Million)
    • 8.7.6. Human Platelet Lysate Market - Argentina
      • 8.7.6.1. Argentina: Human Platelet Lysate Market, by Type, 2019-2032 (USD Million)
      • 8.7.6.2. Argentina.: Human Platelet Lysate Market, by End-Use, 2019-2032 (USD Million)
      • 8.7.6.3. Argentina: Human Platelet Lysate Market, by Application, 2019-2032 (USD Million)

9. Competitive Landscape

  • 9.1. Expansion and Acquisition Analysis
    • 9.1.1. Expansion
    • 9.1.2. Acquisitions
  • 9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

  • 10.1. AventaCell BioMedical Corp
    • 10.1.1. Company Overview
    • 10.1.2. Financial Performance
    • 10.1.3. Product Benchmarking
    • 10.1.4. Recent Development
  • 10.2. Compass Biomedical Inc.
    • 10.2.1. Company Overview
    • 10.2.2. Financial Performance
    • 10.2.3. Product Benchmarking
    • 10.2.4. Recent Development
  • 10.3. Lifescience Group Limited
    • 10.3.1. Company Overview
    • 10.3.2. Financial Performance
    • 10.3.3. Product Benchmarking
    • 10.3.4. Recent Development
  • 10.4. Macopharma SA
    • 10.4.1. Company Overview
    • 10.4.2. Financial Performance
    • 10.4.3. Product Benchmarking
    • 10.4.4. Recent Development
  • 10.5. Merck KGaA
    • 10.5.1. Company Overview
    • 10.5.2. Financial Performance
    • 10.5.3. Product Benchmarking
    • 10.5.4. Recent Development
  • 10.6. Mill Creek Lifesciences LLC
    • 10.6.1. Company Overview
    • 10.6.2. Financial Performance
    • 10.6.3. Product Benchmarking
    • 10.6.4. Recent Development
  • 10.7. Sclavo Diagnostics International Srl
    • 10.7.1. Company Overview
    • 10.7.2. Financial Performance
    • 10.7.3. Product Benchmarking
    • 10.7.4. Recent Development
  • 10.8. Stem Cell Technologies Inc
    • 10.8.1. Company Overview
    • 10.8.2. Financial Performance
    • 10.8.3. Product Benchmarking
    • 10.8.4. Recent Development
  • 10.9. Trinova Biochem GmbH
    • 10.9.1. Company Overview
    • 10.9.2. Financial Performance
    • 10.9.3. Product Benchmarking
    • 10.9.4. Recent Development
  • 10.10. Zen Bio, Inc.
    • 10.10.1. Company Overview
    • 10.10.2. Financial Performance
    • 10.10.3. Product Benchmarking
    • 10.10.4. Recent Development
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦